title: Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients.
abstract: OBJECTIVE
  The aim of this study was to assess the use of 5-fluorouracil (5-FU), leucovorin and oxaliplatin (FOLFOX) regimens in clinical practice according to their efficacy and toxicity.
  
  
  METHODS
  Patients who received oxaliplatin-containing regimens after curative resection for colorectal carcinoma from 10 different oncology centers between May 2004 and December 2009 were included in the study. All patients were treated with FOLFOX regimens. Patients with rectal carcinoma were also treated with chemoradiotherapy with 5-FU after 2 cycles of a FOLFOX regimen.
  
  
  RESULTS
  The median age of the patients was 56 years (range 17-78). Of the total 667 patients, 326 were given FOLFOX-4, 232 were given modified FOLFOX-4 and 109 were given FOLFOX-6. The distribution according to disease stage was 33 patients with stage IIIA colorectal cancer, 382 patients with stage IIIB and 252 patients with stage IIIC. The most common adverse events were neutropenia (54%), nausea (36.9%), neuropathy (38.2%) and anemia (33.1%) for all grades. The median follow-up time was 23 months (range 1-79). Three-year disease-free survival and overall survival were 65 and 85.7%, respectively.
  
  
  CONCLUSIONS
  The different oxaliplatin-containing 5-FU-based adjuvant chemotherapy regimens in patients with stage III colorectal cancer seemed to be at least equal in terms of efficacy regardless of the method of 5-FU administration or oxaliplatin dose.
authors: Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey. doganuncu@yahoo.com
authors: Doğan
authors: D
authors: Uncu
authors: Sercan
authors: S
authors: Aksoy
authors: Bülent
authors: B
authors: Çetin
authors: Tarkan
authors: T
authors: Yetişyiğit
authors: Nuriye
authors: N
authors: Özdemir
authors: Veli
authors: V
authors: Berk
authors: Faysal
authors: F
authors: Dane
authors: Ali
authors: A
authors: Inal
authors: Hakan
authors: H
authors: Harputluoğlu
authors: Burçin
authors: B
authors: Budakoğlu
authors: Doğan
authors: D
authors: Koca
authors: Alper
authors: A
authors: Sevinç
authors: Sener
authors: S
authors: Cihan
authors: Ayşe Gök
authors: AG
authors: Durnalı
authors: Metin
authors: M
authors: Özkan
authors: Mehmet Akif
authors: MA
authors: Öztürk
authors: Abdurrahman
authors: A
authors: Işıkdoğan
authors: Süleyman
authors: S
authors: Büyükberber
authors: Mustafa
authors: M
authors: Benekli
authors: Tuğba
authors: T
authors: Köş
authors: Necati
authors: N
authors: Alkış
authors: Halit
authors: H
authors: Karaca
authors: Nazım Serdal
authors: NS
authors: Turhal
authors: Nurullah
authors: N
authors: Zengin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000740:Anemia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D059248:Chemoradiotherapy; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009503:Neutropenia / Q000139:chemically induced; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil